EFPIA：2024年无法获得和延迟获得创新药物的根本原因：减少患者获得创新药物之前的时间报告（英文版）

The unprecedented speed of innovation exhibited over the last five years and the promise of the industry pipeline provides an important opportunity to improve outcomes for patientsThere is common agreement that the value of innovation is only realised when patients benefit from advances in treatmentHowever, a significant number of medicines are not available across all European Union (EU) marketsEFPIA has studied this through the W.A.I.T. Indicator Survey for many years and has asked CRA to s